Abstract
A feature in the pathophysiology of major depressive disorder (MDD), a mood disorder, is the impairment of excitatory synapses in the prefrontal cortex. Intriguingly, different types of treatment with fairly rapid antidepressant effects (within days or a few weeks), such as ketamine, electroconvulsive therapy and non-invasive neurostimulation, seem to converge on enhancement of neural plasticity. However, the forms and mechanisms of plasticity that link antidepressant interventions to the restoration of excitatory synaptic function are still unknown. In this Review, we highlight preclinical research from the past 15 years showing that ketamine and psychedelic drugs can trigger the growth of dendritic spines in cortical pyramidal neurons. We compare the longitudinal effects of various psychoactive drugs on neuronal rewiring, and we highlight rapid onset and sustained time course as notable characteristics for putative rapid-acting antidepressant drugs. Furthermore, we consider gaps in the current understanding of drug-evoked in vivo structural plasticity. We also discuss the prospects of using synaptic remodelling to understand other antidepressant interventions, such as repetitive transcranial magnetic stimulation. Finally, we conclude that structural neural plasticity can provide unique insights into the neurobiological actions of psychoactive drugs and antidepressant interventions.
Table of contents blurb
Rapid-acting antidepressant interventions, such as ketamine and psilocybin, are thought to enhance neural plasticity. This Review outlines evidence of synaptic deficits in individuals with major depressive disorder, before discussing in vivo longitudinal studies of antidepressant-evoked structural plasticity in rodents. Translational opportunities, research gaps and challenges are also considered.
Introduction
Dendritic spines are the sites of excitatory inputs in pyramidal neurons1. The morphology of dendritic spines is closely related to the presence and strength of excitatory synaptic connections2, which are important parameters defining the wiring of neural circuits. It has long been appreciated from animal studies that psychoactive drugs can induce synaptic plasticity3, which can be observed as changes in the density and size of dendritic spines. Typically, for neocortex, these structural modifications occur after the chronic administration of a psychoactive drug4. Over the last decade, a series of studies used longitudinal in vivo optical imaging to track dendritic spines in the mouse neocortex across days, showing that a single dose of specific drugs leads to long-lasting structural remodeling. Drugs with this plasticity-promoting quality include ketamine5–8, serotonergic psychedelics9,10 and related analogues11,12, which are either approved or being tested in late-phase clinical trials for their rapid-acting antidepressant effects13–15. There is interest from a basic science perspective to understand how these drugs rapidly promote synaptic rewiring. Incentives also exist for pharmaceutical research, which could leverage structural plasticity to screen new chemical entities that might be candidate drugs for treating mental health conditions.
Depressive disorders present in various forms, ranging from mild, temporary episodes to the most severe and debilitating condition, major depressive disorder (MDD). A particularly challenging subset of MDD is treatment-resistant depression, in which individuals fail to respond adequately to first-line antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), prompting the need for alternative treatments. Growing evidence indicates that MDD it is associated with excitatory synaptic deficits16. Rapid-acting antidepressant drugs have been postulated to target synapses by enhancing neural plasticity17; a mechanism that might also be key for other antidepressant interventions, such as electroconvulsive therapy (ECT)18 and repetitive transcranial magnetic stimulation (TMS)19. These interventions can reduce depressive symptoms within days (ketamine20) or a few weeks (ECT21 and accelerated forms of repetitive TMS22). Their therapeutic onset is fairly rapid compared with conventional antidepressant drugs (such as selective serotonin reuptake inhibitors (SSRIs)) and alternative invasive stimulatory techniques (such as deep brain stimulation and vagus nerve stimulation), which can take more than a month to show efficacy. Therefore, given the probable importance of neural plasticity as a potential mechanism of action, preclinical research that delineates antidepressant-evoked effects on the structural rewiring of neurons could shed light on the neurobiology that underlies different treatment options for MDD. Nevertheless, skepticism exists around whether structural plasticity is a sensitive measure or even relevant to the behavioral effects. The adult brain is plastic and synaptic modifications are constantly occurring, particularly after new experiences and learning23–25. Moreover, drugs of abuse (for example, cocaine) with negative behavioral consequences are also known to cause structural plasticity of dendritic spines in the neocortex26,27.
In this Review, we begin by critically reviewing the human data suggesting abnormalities of excitatory synapses in depression, focusing on the prefrontal cortex. We compare the in vivo turnover dynamics of dendritic spines induced by putative rapid-acting antidepressant drugs in preclinical models relative to other types of drugs. We highlight characteristics unique to antidepressant-evoked neuronal remodeling and their potential biological underpinnings. Finally, we discuss the translational opportunities and challenges in using in vivo structural plasticity to advance our understanding of antidepressant interventions.
Excitatory synaptic deficits in depression
To begin, we will first discuss evidence of synaptic deficits and maladaptive plasticity in human studies of patients with depression, as well as the effects of antidepressant interventions on these processes.
Synaptic and morphological abnormalities.
The most direct study of the relationship between dendritic spines and MDD in humans used electron microscopy to analyze postmortem samples from individuals with MDD and showed fewer spine synapses in layer 2/3 of the dorsolateral prefrontal cortex compared to healthy controls28. Moreover, there are reports of reduced expression of dendritic markers and synaptic proteins associated with MDD28,29. Positron emission tomographic (PET) imaging of synaptic radioligands reveals diminished signals in the prefrontal cortex, anterior cingulate cortex and hippocampus of patients with MDD compared to healthy controls, with the amount of synaptic signal reduction correlating to the severity of depressive symptoms30. In agreement, in vivo magnetic resonance spectroscopy of individuals with MDD indicates lower glutamate and glutamine concentrations in frontal cortical regions compared to healthy controls1,32. As an integral component in excitatory neurotransmission, such evidence for diminished glutamate signalling is indicative of synaptic deficits in MDD. However, questions remain regarding the origin of the signal from metabolic versus neurotransmitter pools and relative contributions from neuronal and glial cells33. Nevertheless, these convergent pieces of evidence suggest excitatory synaptic impairments in MDD.
Genomic and transcriptomic studies have strongly implicated excitatory synaptic dysfunction and prefrontal cortical regions in MDD34,35. In a meta-analysis of >1.2 million individuals, three of the eight most significant gene ontology categories associated with depression are synapse assembly, synapse organization and synaptic signaling; of note, some of the included studies used formally diagnosed MDD and others a broader definition of depression35. In another large-scale analysis, four out of five gene sets enriched in depression phenotypes encode cellular components for excitatory synapse, neuron spine, post-synapse and dendrite, therefore emphasizing excitatory synaptic function and structure as a major site for perturbance in depression36. These and other genome-wide association studies have also identified specific risk genes that could contribute to the synaptic deficits, including those supporting glutamatergic ionotropic and metabotropic receptors, dopamine receptors, calcium-binding proteins36, as well as genes involved in synapse development, presynaptic vesicle trafficking and synapse-related major histocompatibility complex function37. Bulk and single-cell RNA sequencing of MDD and control postmortem patient samples similarly reveal altered expression of genes related to synaptic transmission and regulation of synaptic plasticity associated with MDD38,39.
Structural magnetic resonance imaging (MRI) studies of patients with MDD have consistently reported a reduction in cortical thickness and grey matter volume in certain brain regions. These effects were initially described in the hippocampus40 and subgenual prefrontal cortex41, but gross volumetric changes are also evident in anterior cingulate cortex, orbital frontal cortex, amygdala, insula and other locations42,43. Yet, questions remain about the effect size and whether these changes are a consequence of or a precursor to MDD44. Moreover, postmortem MDD patient samples showed loss of brain volume in the prefrontal cortex is accompanied by abnormalities at the cellular level, which include decreased size and density of neurons and glial cells45. Therefore, synapse loss in the neuropil can contribute to a potential decrease in brain volume; however, it would probably be only one of several relevant factors.
Maladaptive plasticity and functional connectivity.
Non-invasive neurostimulation techniques such as TMS can be used to produce motor-evoked potentials (MEPs) in humans. Single-pulse TMS delivers isolated magnetic pulses, primarily for diagnostic or brain mapping, while repetitive TMS (including accelerated TMS) involves protocols that apply a series of high-frequency stimulation for therapeutic purposes. Changes in MEPs induced by both single-pulse and repetitive TMS, as measured by electromyography or electroencephalogram recordings, are thought to be indicators of synaptic plasticity in the stimulated circuits. For instance, the paired associative stimulation (PAS) paradigm modulates corticospinal plasticity by applying repeated stimuli to the peripheral median nerve and the contralateral motor cortex46. These PAS-induced changes to MEPs can be blocked by administering an N-methyl-D-aspartate (NMDA) receptor antagonist46, which suggests a mechanism involving excitatory synaptic plasticity. Individuals with MDD show no change in MEP amplitude after paired associative stimulation, unlike healthy control individuals47. Of note, the deficient MEP response to PAS observed in MDD can return to a normal level with remission of depression, suggesting that the corticospinal plasticity tracks recovery48. While these findings require replication in larger cohorts, the approach reveals a potential deleterious consequence of excitatory synaptic deficits in MDD. Although the PAS paradigm has been primarily demonstrated in the motor cortex, modified protocols have been developed to target the dorsolateral prefrontal cortex, revealing maladaptive neural plasticity in individuals with MDD49. These studies are promising but preliminary, with drawbacks including the variation in stimulation effects depending on ongoing brain activity and the large inter-individual and intra-individual variability50.
Functional MRI is used to investigate circuit-level dynamics in human volunteers. Although resting-state functional connectivity is not a specific readout of synaptic activity, it is an aggregate measure that necessarily incorporates synapse-level signalling. A large consortium study of 1,300 individuals with MDD identifies hypoconnectivity within the default mode network as a hallmark of the disease51. Moreover, this result was replicated in another multi-center study of over 600 patients with MDD52. Multiple smaller-scale meta-analyses of individuals with MDD have instead reported hyperconnectivity within the default mode network53,54. Hypoconnectivity within the frontoparietal network has been reported as a marker of MDD53, but was absent in a later investigation51. These contradictory results might be attributed to the substantial heterogeneity in the presentation of depression55–57; even the most robust depression-associated features have been shown to have extremely small effect sizes when assessed using common neuroimaging modalities58. Identifying depression-associated and treatment-associated changes within and between specific networks and circuit pathways remains a critical yet elusive goal. However, the hope is that advancements in precision functional mapping, through densely sampled longitudinal data from the same individuals, could soon make this possible59,60.
Antidepressant interventions.
In individuals with MDD, the effect of antidepressant interventions on excitatory synaptic deficits is not well understood. Non-invasive neurostimulation via repetitive TMS of the left dorsolateral prefrontal cortex has impressive efficacy as an antidepressant treatment22,61,62. One study suggests that MEPs are reliably increased in MDD patients after repetitive TMS treatment, a strengthening that correlates with the improvement in depressive symptoms63. The electrophysiological and symptom changes in MDD patients induced by repetitive TMS can be facilitated by co-treatment with D-cycloserine64, which as a partial NMDA receptor agonist is expected to boost excitatory synaptic plasticity. Magnetic resonance spectroscopy shows elevated prefrontal glutamate and glutamine metabolite levels of individuals with depression after ketamine treatment65 and after ECT66. The degree of ECT-related change in glutamate in anterior cingulate cortex correlates with the behavioral outcome67.
The relevance of excitatory neural plasticity to the overall treatment mechanism remains unclear owing to two main challenges for human studies. First, is the issue of causality, as individuals with MDD are often already on a course of SSRIs or might have only recently discontinued psychiatric medications, making it difficult to disentangle and isolate the effect of the treatment under study. Second, progression is not tracked longitudinally and currently no method is available to interrogate synapse-level changes directly and repeatedly in humans. For these reasons, animal models provide a unique opportunity for studying how antidepressant interventions affect neural plasticity. Preclinical studies have shown that dendritic spines in cortical neurons are targeted for remodelling by ketamine68, classic psychedelics (for example, psilocybin and 5-MeO-DMT)69,70, ECT71 and repetitive TMS72,73. These early studies paved the way for studying the effect of antidepressant interventions on structural plasticity but relied on in vitro preparations or histological methods that only assess a single time point. The latest animal studies over the last decade have leveraged chronic imaging to longitudinally track dendritic spines in the brain in vivo, which has been particularly valuable in uncovering the dynamic rewiring process and delineating time courses. These advances are our focus for the next section.
Longitudinal preclinical studies of antidepressant-evoked structural plasticity
Here we will evaluate the nuanced changes of drug-evoked plasticity in mice in response to antidepressant drugs compared to other psychoactive drugs.
Antidepressant drugs versus other drugs.
In the mammalian neocortex, most excitatory synapses are located at dendritic spines in pyramidal neurons (Box 1). Laser scanning two-photon-excited fluorescence microscopy can be used to track structural neural plasticity by imaging the turnover of dendritic spines in the mouse (Figure 1; Box 2). Most in vivo imaging studies of antidepressant treatments so far have focused on antidepressant drugs. Here, to illuminate the crucial plasticity mechanisms, we summarize published studies5–12,74–80 that have quantified the dynamic turnover of dendritic spines in mice following the administration of putative rapid-acting antidepressant drugs, and contrast them with responses to other psychoactive drugs (Supplementary Table 1).
Box 1: Dendritic spines as a proxy for excitatory synapses.
Most dendritic spines are sites of excitatory synapses. Upon sensing glutamate released from apposing presynaptic terminals, dendritic spines depolarize and the electrical signals spread for neuronal communication. Biochemically, the spine’s unique head-and-neck geometry suggests that certain molecular signals are compartmentalized to facilitate spine-specific plasticity162,163. During postnatal development, synaptic connections are created and pruned, resulting in high spine turnover rates164. In the mature brain, structural plasticity slows down to maintain a fairly steady number of synapses164, yet new spines can still be formed or existing spines be eliminated in response to novel experience25 and learning23,24, or in neuropsychiatric disorders165. New dendritic spines emerge after the induction of long-term potentiation166.
A foundational assumption of this review is that the existence of a dendritic spine indicates the presence of an excitatory synapse onto the cortical pyramidal neuron. Electrophysiology supports this assumption: for example, the frequency of miniaturized postsynaptic currents is considerably increased the day after psilocybin administration in mice, demonstrating enhanced excitatory neurotransmission that corroborates the imaging results showing enhanced spine density9. More direct evidence came from electron microscopy that can resolve dendritic spines at high spatial resolution153,167. Early studies suggest 70–95% of the excitatory synapses onto cortical pyramidal neurons are formed at dendritic spines1. A more recent study shows that only 3.6% of Golgi-stained, optically imaged spines in the mouse neocortex lack synapses167. Whether these spines are functional is less clear, however, as a recent report based on expansion microscopy and patch-clamp recording suggests that up to 25% of the dendritic protrusions in layer 5 pyramidal neurons in the adult mouse brain are filopodia-like, electrically silent synapses99. Collectively, these results indicate that almost all dendritic spines contain synaptic elements, with the majority being functional excitatory synapses.
The size of a dendritic spine is thought to be an indicator of synaptic strength. Larger spine volumes are positively correlated with larger postsynaptic densities and a higher number of presynaptic vesicles153. Moreover, targeted potentiation of a single spine by glutamate uncaging leads to structural enlargement, which is accompanied by the recruitment of AMPA receptors and increased excitatory post-synaptic currents168. Finally, spine head volume is shown to correlate strongly with postsynaptic density area, which directly relates to the amplitude of postsynaptic potential169. These results show the tight relationship between spine size with function and stability2. Other morphological parameters could have biological implications too, such as the length of the spine neck protrusion, which is expected to affect the compartmentalization of the biochemical signals162,163.
Figure 1: Imaging dendritic spines in vivo.

(a) visualizing and tracking dendritic spines in an intact brain was made possible by multiphoton microscopy157. The approach begins with cranial window surgery involving either thinning the skull158 or removing a bone flap and putting on a 1–10 mm2 glass cover116. The cranial window is essential for optical transmission into the brain. To visualize dendrites at subcellular resolution, mice are typically anesthetized with the head fixed in a two-photon microscope. Neurons express fluorescent proteins, which are introduced using viruses or by generating transgenic animals. (b) Cartoon representations of in vivo images obtained from focal planes at the apical tuft of a deep-lying pyramidal neuron. Subcellular resolution imaging enables visualization of dendritic segments including dendritic spines (solid arrowhead) as well as axons (arrow) and filopodia (asterisk). If only a small protrusion is observed, the presence of a spine can be confirmed by checking adjacent images at different depths. Dendritic spines are small structures that protrude off the shaft of a dendrite, with a typical length of <2 μm and a stalk as narrow as 0.1 μm159. Spine morphology varies widely, ranging from slender filaments to mushroom shapes1. Spine number density and spine head width can be measured from the images. Thick-tufted layer 5 pyramidal neurons have been estimated have ~15,000 spines distributed across the apical, oblique and basal compartments of the dendritic tree160. The mouse neocortex has an average of 10–15 spines per 10 μm of dendrite153, although the number differs depending on cell type and dendritic location161 shapes1. (c) Dendritic spines in the same field of view can be tracked across multiple sessions over weeks. Here, the same field has been tracked in seven sessions over 38 days; persisting stable spines and new spines can be measured. Part c is reprinted with permission from ref.9, Elsevier.
Box 2: Longitudinal imaging of dendritic spines in the neocortex of living animals.
When imaging dendritic spines, expression of fluorescent proteins in a sparse number of neurons is highly desirable to prevent fluorescent dendrites from overlapping and obscuring each other in the images. As such, many studies rely on Thy1GFP and Thy1YFP mouse strains, which have stable and bright fluorescent protein expression in a sparse subset of neurons170. Standard two-photon microscopy offers a spatial resolution of ~0.2 μm laterally and ~1.5 μm axially171, which is sufficient to visualize dendritic spines, especially those that lie parallel to the focal plane. However, axially oriented spines or thin filopodia can be missed and small features such as spine neck width cannot be resolved Nevertheless, structural properties including the number density, head width and protrusion length, can be quantified from the images, based on morphological criteria116. Some studies classified spines into subtypes (for example, mushroom, stubby and thin)1, although other ultrastructural analyses suggest that sizes and shapes might lie on a continuum rather than distinct subtypes172. Imaging can be repeated for the same field of view, therefore visualizing longitudinal changes of dendritic architecture in a live animal over an extended period across days and up to several months is feasible.
The number of dendritic spines in the brain is maintained through a balance of the formation of new spines and the elimination of existing spines. Using the longitudinal imaging approach, pioneering studies have investigated the baseline levels of dendritic spine turnover in layer 5 pyramidal neurons in the neocortex of adult mice. One study indicates that dendritic spines are mostly stable, with only ~4% of them turning over each month, suggesting that many spines persist through a rodent’s lifetime173. By contrast, another study shows a more dynamic picture, observing that ~20% of dendritic spines have lifetimes of <1 day and ~60% have lifetimes of >8 days, with an estimated mean lifetime of 4 months for the enduring spines25. The discrepancy could be due to distinct stable and transient subpopulations of dendritic spines intermixed along cortical dendrites174. Moreover, the spine turnover rate can vary for different brain regions; for example, the mean lifetime reported for hippocampal dendritic spines is as short as 1–2 weeks175. Overall, these results demonstrate that the structural plasticity of dendritic spines is a process not limited to development but that continues in adulthood.
We first consider a subset of these experiments in which dendritic spine density in cortical pyramidal neurons has been tracked over many days, surveying three drugs with known and putative therapeutic effects for MDD in humans (ketamine5, 5-MeO-DMT10 and psilocybin9) and four drugs of other classes (allopregnanolone74, diazepam74, zolpidem74 and cocaine75). Spine density data are available longitudinally through 7–15 imaging sessions, covering from pre-drug to 15 days post-drug administration for ketamine and 63 days post-drug administration for diazepam. Some experiments test a single dose of the compound whereas others involve chronic administration. The drugs act on various receptors and transporters with distinct synaptic localization (Figure 2a).
Figure 2: Effects of different psychoactive drugs on apical dendritic spines of cortical pyramidal neurons in mice.

(a) Seven drugs and the putative synaptic localization of their primary target receptors and transporters, for which there are published data on their long-term effects on dendritic spines in mice. (b) Effects of the drugs on the density of cortical dendritic spines. Data values were extracted from published studies5,9,10,74,75. The studies, conducted in different laboratories, all used two-photon imaging to visualize apical dendritic spines of deep-layer pyramidal neurons in the neocortex. The studies differ in the imaged brain region, which was medial frontal cortex for ketamine, 5-MeO-DMT, psilocybin and cocaine, and somatosensory cortex for diazepam, zolpidem and allopregnanolone. The studies also differ in the number of drug administrations, indicated by the arrows. To plot the results on the same axes, values were extracted from published plots in pixel measurements using ImageJ and scaled relative to the y axis of the respective plot. Scaled drug-treated values were subtracted from scaled vehicle-treated values. All the extracted and subtracted values are provided in the Supplementary Data.
Ketamine, primarily an NMDA receptor antagonist81, has been studied at subanesthetic doses and is an FDA-approved medication for treatment-resistant depression20,82. 5-MeO-DMT and psilocybin act on serotonergic receptor subtypes83,84, which together with other classic psychedelics have long been recognized for their therapeutic potential85 and are undergoing clinical trials to test as treatments for MDD and treatment-resistant depression86–88. Allopregnanolone, a positive allosteric modulator of the GABAA receptor though via binding on the neurosteroid site89, is approved for treating postpartum depression. Diazepam and zolpidem, also positive allosteric modulators of the GABAA receptor90, are benzodiazepines administered to treat anxiety and insomnia. Cocaine inhibits the uptake of monoamine neurotransmitters such as via its action on the dopamine transporter, and is a drug of abuse90. Here, we list the primary targets, although these drugs probably interact with other receptors. For instance, ketamine and its metabolites can act on NMDA receptor-independent signalling pathways, including opioid receptors81.
For visualization, we have extracted data values from the published studies (Supplementary Data; Box 3). Plotting the results across studies on the same axes reveals that the drugs exert differential effects on dendritic spine density in cortical pyramidal neurons (Figure 2b). A single dose of ketamine5, 5-MeO-DMT10 or psilocybin9 in mice rapidly increases the spine number density of cortical pyramidal neurons by 12–20%. In the ketamine study, the spine density starts to decline after 2 weeks5, but stays elevated for at least 1 month in the 5-MeO-DMT and psilocybin studies9,10. By contrast, allopregnanolone74 and cocaine75 also cause the spine density to rise, but the change is more gradual, weaker (increase of ~5%), and occurs after repeated administration. For diazepam74, 1 week of daily exposure robustly reduces the spine number density; an effect that lasted for 2 months. No detectable change was observed after chronic administration of zolpidem74.
Box 3: Methodological considerations.
The published preclinical studies presented in Figure 2 have methodological differences. The effects of ketamine5, 5-MeO-DMT10, psilocybin9 and cocaine75 were determined by imaging apical tufts of layer 5 pyramidal neurons in the Cg1/M2 region of the mouse medial frontal cortex. By contrast, studies of the various GABAA positive allosteric modulators were done in the mouse somatosensory cortex; however, some results were replicated in a separate experiment that imaged the prelimbic region of medial frontal cortex74. Although imaging dendritic spines in vivo across the entire brain is currently not feasible, future studies could start with a brain-wide characterization of plasticity-related changes, such as an unbiased screening of synaptic proteins or immediate early genes176,177, before focusing on specific brain regions. Dendritic spines in deep-lying brain regions can be imaged in live animals using a glass microprism8 or through a cannula178. Moreover, the studies used adult mice with ages ranging from 2–2.5 months for psilocybin9 to 4–5 months for diazepam74. In studies that used younger mice, spine loss was reported for vehicle-treated animals5,6, which might be due to synaptic pruning from still-going cortical development, accumulating photodamage from repeated imaging, or the degrading quality of the cranial window over time. The influence of age is an important reason to study drug effects in vivo rather than with dissociated cells in vitro, which contain immature cells reflecting embryonic stages of development.
Timing and dose.
One theme that emerges through the comparison is that although drug-evoked changes in spine density can last for days and up to weeks, the initial shift in the dynamic turnover rates of spines is transient. Compounds with putative rapid-acting antidepressant action (ketamine, psilocybin and 5-MeO-DMT) heighten the rate of spine formation for 1–3 days after single-dose administration5,9,10. For ketamine, the speed of spine growth has been finely mapped by two studies, which show that higher spine density could be observed at 12 hours post-injection, but not earlier8,91. Even for other chronically administered psychoactive drugs, spine remodeling kinetics are quick and restricted to the few days after treatment onset. This is true for in a study of Δ9-tetrahydrocannabinol (THC), which has the highest spine gains on day 1 and day 3 despite a 12-day course of administration80, and also true for cocaine, in which spine rearrangement is seen within hours after the first injection75,92. Likewise, a next-day increase in spine formation in vivo is reported for haloperidol (an antipsychotic that is a D2 receptor antagonist77), 2,5-dimethoxy-4-iodoamphetamine11 (DOI, a substituted amphetamine that is also a phenethylamine psychedelic) and tabernanthalog11,12 (TBG, a novel serotonergic agonist derived from ibogaine).
Dose is probably a major factor in determining the kinetics and effect size of the drug-evoked structural plasticity, but unfortunately is often not tested in in vivo imaging studies. For diazepam, a high sedative dose at 5 mg/kg leads to an immediate loss of spines, whereas a lower anxiolytic dose at 1 mg/kg has similar but blunted effects74. The length of administration matters: 4 weeks of a high dose of diazepam is associated with a more long-term decrease in spine density than the same dose applied for 1 week. Another example is ketamine, in which four studies from four different laboratories have investigated the effects of an antidepressant dose at 10 mg/kg, either via a single injection5,7,8 or sub-chronic administration for 2–7 days6,7. All studies report a subsequently increased number of cortical dendritic spines. However, when ketamine was tested at a much higher, anesthetic dose (85 mg/kg) and in conjunction with xylazine, the drug only transiently promotes the formation of filopodia for 1–4 hr and has no lasting effect on the dendritic architecture78. Furthermore, without testing a range of doses or inclusion of another drug as a positive control, it is not easy to interpret a null result. For example, one study reported no effect in the visual cortex following 4 weeks of treatment with the antidepressant drug, fluoxetine76, but perhaps a higher dose would yield a different result.
Wiring or weight changes?
When a new spine is formed, it could arise from de novo spinogenesis or from the conversion of an electrically ‘silent synapse’ (Figure 3). During de novo spinogenesis, spine outgrowth occurs at a dendritic location previously lacking synaptic material. This type of glutamate-evoked sprouting can involve the initial growth of a small protrusion93 that gradually increases in volume with maturation94,95. Ketamine has been shown to enhance such glutamate-evoked spinogenesis91. The possibility of de novo spine formation in response to ketamine is exciting, as it suggests that the drug might increase the number of potential synaptic partners for a given dendritic segment. The prospect for a cell to form synapses with previously unconnected partners confers a high degree of flexibility to the wiring of cortical circuits96.
Figure 3: The life cycle of a dendritic spine.

A functional dendritic spine with a complement of AMPA receptors and N-methyl-D-aspartate (NMDA) receptors (in gray box) can emerge through de novo formation (spinogenesis) from a location that lacks any synaptic material or conversion from an electrically ‘silent synapse’, which contains only NMDA receptors. The size of a dendritic spine can be enlarged or shrunk continually to adjust the synaptic strength. A spine can persist for some time, ranging from days to months, before it is eventually retracted and eliminated. In addition, a potential path could exist for the back-conversion from functional dendritic spine to a silent synapse (dashed arrow).
Alternatively, new spines could be attributed to the conversion of silent synapses to active synapses. Silent synapses contain NMDA receptors and are electrically silent97, but recruit AMPA receptors upon synaptic activation (Figure 3)98. Although silent synapses resemble filopodia and are thus easily missed by in vivo two-photon microscopy, most of them have functional presynaptic partners99. Therefore, unlike de novo spinogenesis, the wiring for silent synapses has already been laid out, but the connections are dormant. An intriguing idea is that the spine loss observed in depression might not be elimination, but rather the conversion of functional synapses into silent synapses, which could then be reactivated by rapid-acting antidepressants. This scenario could explain why several studies in mice have reported that new spines induced by ketamine7,8 or serotonergic agonists12 preferentially form at locations where spines were recently eliminated.
Empirically, psychoactive drugs might affect both spine number density and spine size, but the changes could occur in different directions or over different time courses. Following a single dose of psilocybin in mice, both spine number density and spine head width significantly increase9, whereas diazepam induces significant decreases in these parameters on a similar timescale.74. By contrast, a single dose of 5-MeO-DMT rapidly elevates spine number but has minimal effect on the spine size10. Of note, after psilocybin treatment, the initial coordinated elevations in spine number and size diverge over time, with spine density remaining enhanced and spine size returning to baseline after a month9. A tantalizing prospect is that spine number and spine size reflect different forms of synaptic plasticity. This idea is supported by attempts to causally induce structural plasticity. Two-photon glutamate uncaging can be used to study the targeted stimulation of individual dendritic spines. Applying a spike-timing-dependent glutamate uncaging protocol to single spines in mouse brain slices was sufficient to convert silent synapses to functional synapses, but the same protocol was ineffective at enlarging existing spines99. This finding suggests that different plasticity processes are responsible for spine formation versus enlargement (Box 4), which could reflect different mechanisms of drug action.
Box 4: Molecular factors involved in spine formation and elimination.
Spine growth involves the structural expansion of spine volume and can be the result of de novo spinogenesis or enlargement of existing spines. The spine expansion process is well characterized, especially through careful studies using two-photon glutamate uncaging for targeted stimulation of individual dendritic spines in brain slices. The general consensus on the process is a protein synthesis-independent early phase (as demonstrated by applying protein synthesis inhibitors such as anisomycin or cycloheximide and observing no impediment to initial spine enlargement179) followed by a protein synthesis-dependent late phase179. In the early phase (<60 min), actin and cofilin transiently accumulate in the spine head. From there, actin rapidly undergoes polymerization and actin-modifiers are recruited, which enables major reorganization of the actin cytoskeleton to enlarge the spine head. This initial step of actin remodeling involves small GTPases downstream of CaMKII, such as H-Ras, Cdc42 and RhoA162. An early, postsynaptic release of brain-derived neurotrophic factor (BDNF) and rapid spine-specific activation of TrkB receptors also occur180.
The late phase (>60 min) involves protein synthesis including local translation in the dendrites181. For example, PSD-95 is newly synthesized in response to synaptic stimulation (see the figure), as shown using novel fluorescent epitope tags182. PSD-95 and other scaffold proteins are recruited to the spine head, at rates that correlate with the eventual increase in spine volume. The scaffold proteins contribute to the enhanced retention of glutamatergic receptors at synapses, thereby resulting in synaptic potentiation183. Of note, these time courses were delineated in vitro but are challenging to confirm in vivo due to technical limitations. In vivo, newly formed spines might take a longer time (>1 and up to 4 days) to become functional synapses94. For spine elimination, shrinkage and eventual retraction involve a different sequence of molecular signals184. Synapse formation and elimination are additionally regulated by non-neuronal cells such as astrocytes and microglia185,186. Box 4 figure is adapted from ref.187, Springer Nature Limited.
Persistent integration of newly formed dendritic spines.
A striking finding in antidepressant-evoked structural plasticity is the sustained increase in dendritic spine density. The extended time course of the circuit rewiring seen in mouse models is reminiscent of the durable therapeutic effects reported in clinical trials. It is tantalizing to think that the clinical outcomes of psilocybin and ketamine treatments could reflect their different effects on spine persistence in preclinical studies. The more long-term effects of psilocybin on dendritic spine density correspond with its ability to provide more sustained relief from depressive symptoms compared with ketamine (Figure 2). However, the reason behind this persistence of dendritic spines is poorly understood.
Prevailing frameworks of antidepressant drug action have mostly focused on how synaptic connections can be potentiated17,100, although the theory of a homeostatic plasticity basis for drug action could speak also to maintenance and stability101. In general, some dendritic spines are ephemeral, disappearing within several days after formation, whereas others can remain for months102. Moreover, larger dendritic spines are known to be more persistent than smaller ones102,103. A drug might selectively favor the growth of larger and more persistent spines. For psilocybin, ~50% and 35% of the newly formed spines induced by drug administration in mice survive for 7 and 34 days respectively9, suggesting that a sizable portion of the new connections are stabilized and maintained. These values contrast with the lower rate of persistence (~20%) for ketamine-evoked new spines after 15 days5. As another example, diazepam seems to selectively promote the loss of transient spines while sparing the more persistent, pre-existing spines74, which might explain why its chronic use impairs learning.
Interactions between stress and dendritic plasticity.
An underexplored topic is the interaction between antidepressant interventions and prior experiences that can also evoke neural adaptations. For example, whether antidepressant interventions and stress engage the same or different structural plasticity mechanisms is not currently clear. Chronic stress is a risk factor for depression in vulnerable individuals104, motivating a variety of preclinical models in which repeated stressors were applied to rodents. These models cannot recapitulate the complexity of depression, but could still be useful tools for understanding biological mechanisms105,106.
In rodent medial frontal cortex, chronic stress causes atrophy of apical dendritic arborizations107,108 and retraction of dendritic spines109,110. Studies from the past 15 years using in vivo longitudinal two-photon imaging have confirmed these structural changes, finding decreased spine density in cortical pyramidal neurons of mice following repeated restraint stress7,8,111, chronic unpredictable stress12,112 or chronic corticosterone treatment8,113. A heightened rate of spine elimination is a main factor underlying the stress-induced spine loss111,113, which seems to selectively disturb specific dendritic branches and spatially clustered dendritic spines8. Evidence indicates that the effect of ketamine on dendritic architecture depends on prior stress exposures in mice. For example, an increase in spine formation rate was observed when ketamine was given to mice that were stressed with repeated restraint7. However, if ketamine is applied prophylactically prior to restraint stress, ketamine-treated mice are protected against stress-induced spine elimination, but no longer have additional new spines. Furthermore, in a tour-de-force demonstration in mice, a single dose of ketamine specifically restored dendritic spines that were eliminated after chronic exogenous corticosterone (the key glucocorticoid hormone of the stress response in rodents) treatment8. The spinogenesis occurs after the acute action of ketamine to increase calcium influx at dendritic spines114 and the induction of synchronous neuronal firing8 in the medial prefrontal cortex8, which could be potential pre-requisites to the structural plasticity.
Translational opportunities
Towards an assay for drug screening.
Structural plasticity in vivo could be leveraged for preclinical drug discovery, as currently few assays are available with predictive validity for psychiatric disorders115. There is value in pursuing a measurement that probes directly inside the brain and yields more nuanced information about drug action than other methods, such as behavioural tests and biochemical assays. Challenges exist in scaling up in vivo imaging-based drug screening assays due to low throughput, but advancements in technology and methodology could soon help overcome these limitations.. One issue is the image analysis, which involves human observers segmenting regions of interest based on pre-determined criteria116. Machine learning can automate the process to accelerate the analysis of dendritic spines117,118. Moreover, automating the analysis will also improve reliability, as currently different experts can annotate differently and, even for the same expert tested weeks apart, intra-rater reliability remains less than ideal117. Another viable approach to increase throughput is to first use in vitro high-content imaging of cultured cells to perform a large-scale screen of hundreds of compounds for increased dendritic spine growth or synaptic protein expression69,119,120, which has the added advantage of potentially including human patient-derived neurons121, before selecting a few promising candidates for in vivo characterization.
A biomarker for synaptic remodeling.
Although visualizing dendritic spines in vivo in non-human primates (such as marmosets and macaques) is possible122,123, ultimately animal studies are insufficient if the goal is to understand human brain function. The issue of species-specific differences in neuroanatomy is important, given the uniqueness and complexity of the human prefrontal cortex. Moreover, depressive symptoms are not only heterogeneous, but they can also have different trajectories over time. The key to resolving these unknowns will be new methods that can measure synapse-level changes in the human brain while tracking the progression of depressive symptoms.
For studying synaptic-level changes in humans, the most promising approach is PET imaging. Novel contrast agents, such as [11C]UCB-J or [18F]UCB-J and [18F]SynVesT-1, have micromolar-affinity to synaptic vesicle glycoprotein 2A (SV2A), a synaptic vesicle protein that is expressed in pre-synaptic terminals throughout the brain. When applied to patients with MDD, this imaging approach reveals that the severity of depressive symptoms negatively correlates with SV2A density30. Moreover, in MDD patients with lower SV2A density at baseline, the administration of ketamine leads to a significant increase in the SV2A signal, whereas no change is for healthy individuals and in MDD patients with no prior evidence of synapse loss124. Another study detected no change in synaptic signal in patients with late-life depression (over 60 years of age) being treated with first-line antidepressant medications relative to the healthy control group125. A caveat of SV2A imaging is that an increase in signal can be due to more synapses or stronger existing synapses, which the method cannot disambiguate. Moreover, longitudinal PET imaging across multiple sessions could be cost-prohibitive and additional difficulties can arise that are associated with quantification of nonspecific SV2A binding126. Notwithstanding the challenges, synaptic imaging in vivo in humans is gaining popularity. Similar to preclinical in vivo optical imaging, synaptic imaging in humans might soon make it possible to compare effects across drug types, as data begin to emerge for SSRIs127 and drugs of abuse128.
Gaps and challenges
Causal link from drugs to synapses and from synapses to behavior.
While rapid-acting antidepressant drugs promote the formation and growth of dendritic spines in animal models, whether this effect is an epiphenomenon or an essential step towards behavioral effects is not understood. An important piece of the puzzle is that the rapid-onset and long duration of spine density change in mouse models coincide with the time course of improvements seen in patient depression rating scales (Figure 4a). Importantly, other evidence suggests that drug-evoked neuronal rewiring could be relevant to behavioral outcomes. The first clue comes from a study of rats that underwent repeated restraint stress, which caused impairments in attentional set-shifting (a measure of attention and cognitive flexibility)129. For stressed animals, the loss in dendritic material correlates significantly with the reduction in behavioral performance. A second clue is that in mice administered with cocaine, the persistence of drug-evoked new spines relates to the bias in the conditioned place preference test (a test of preference for an addictive drug)75. The third piece of evidence, and the most direct proof so far, comes from experiments involving causal perturbation. Newly formed spines can be selectively manipulated to shrink and collapse using a light-activated tool that disrupts cytoskeleton dynamics130. A crucial study showed that disrupting ketamine-evoked new spines blocks the ability of the drug to alleviate motivated escape behavior in mice8. Intriguingly, the manipulation affects specifically the sustained behavioral responses, but not the acute action, suggesting that ketamine-induced spine formation might be more relevant for the long-term clinical effect of the drug. It will be essential for future studies to confirm this causal relationship for ketamine, and to further test the link for other antidepressant interventions. Assuming the new excitatory synapses are essential for antidepressant action, there remain open questions as to what exactly are downstream mechanisms that enable the new spines to drive behavioral changes.
Figure 4: Time courses of antidepressant intervention-evoked structural neural plasticity in rodents and therapeutic-onset in humans.

(a) Schematics illustrating the timing of events after rapid-acting antidepressant drugs, including the elevation in dendritic spine formation rate in medial frontal cortex in mice (green) and the increase in dendritic spine density in medial frontal cortex in mice (yellow) as measured by laser scanning two-photon-excited fluorescence microscopy, and the therapeutic onset when a notable decrease in depressive symptoms can be detected for human patients measured by Hamilton Depression Rating Scores or Montgomery-Asberg Depression Rating Scale scores with treatment-resistant depression (blue) after one or more treatment sessions (black arrowhead). (b) Similarly to (a) for accelerated TMS. The dashed lines and question marks denote hypothesized structural plasticity. All profiles are schematic but based on data from published studies (ketamine spine formation and density timing5,8; ketamine therapeutic onset20; psilocybin spine formation and density timing9; psilocybin therapeutic onset86; TMS therapeutic onset22)
Towards reverse translation of TMS.
Although studies have used in vivo structural plasticity to study antidepressant drugs, a clear opportunity exists here to apply the same approach to understand other interventional psychiatry treatments (Figure 4b). Consider TMS: in preclinical studies, a single pulse leads to a short-lived and localized increase in spiking activity and then suppression over ~100 ms131,132. By contrast, high-frequency repetitive TMS favors excitation and subsequent long-term potentiation of the evoked activity131. The consequences on dendrites are interesting to consider. One study shows that a single pulse of TMS reduces sensory-evoked calcium signals in rodent cortical dendrites133. The inhibitory effect could arise from the depth dependence of TMS, as dendrite-targeting GABAergic cells in layer 1 are strongly activated, whereas the pyramidal cell bodies in layer 5 are far from the coil and therefore not driven133. Evidence from preclinical studies now suggests that repetitive TMS could evoke the remodelling of dendritic spines in vivo134; however, the effect of clinically relevant high-dose TMS protocols (such as intermittent theta-burst stimulation) on structural neural plasticity remains to be determined. A challenge for reverse translation of repetitive TMS is the vast difference in brain geometry between animals used in preclinical studies and humans. The spatial extent of the magnetic field stimulation should match the brain targets, such that the coils used for TMS in humans need to be miniaturized for preclinical experiments.
Which circuits and cell types?
At face value, given the excitatory synaptic deficits in prefrontal cortex associated with MDD, it seems that the formation of new dendritic spines evoked by rapid-acting antidepressant drugs should be beneficial. However, this view is overly simplistic because not all synapses are equal. The function of synapses in neural circuits depends critically on the source of the presynaptic input, the subcellular location in the postsynaptic cell and the postsynaptic cell type in different brain regions. Although our discussion focuses on dendritic spines in the frontal cortex, the pathophysiology of depression involves a broad neural circuitry. In humans with depression, maladaptive plasticity and abnormalities are observed in the frontoparietal network, default mode network, salience network and the limbic system53,135,136. Increasing evidence also indicates that subcortical structures, such as amygdala, nucleus accumbens, ventral tegmental area and dorsal raphe, have critical roles in mediating the diverse symptoms of depression137. Preclinical research suggests region-specific differences in the pathophysiology. Although chronic stress causes excitatory synaptic deficits and dendritic spine loss in the rodent medial frontal cortex109,138, opposing effects have been observed in the amygdala139,140 and lateral habenula141,142.
Structural changes have different implications depending on the connectivity of a brain region with the broad neural circuitry, therefore increased dendritic spine density and spine size should not be interpreted as blanket beneficial attributes. A more likely scenario is that not all new spines are equally important; instead, those that strengthen specific circuit pathways might be particularly crucial for behavioral effects. Future studies should examine how structural plasticity can be modified in a circuit-specific manner by stress143 and drugs144,145. Dual-color imaging could be used to visualize dendritic spines while at the same time identifying the source of presynaptic input146. Drug-evoked changes in the distribution of synaptic partners could be systematically assessed across the whole animal brain during monosynaptic anterograde and retrograde viral tracing methods147,148. It will be crucial to understand the specific circuit pathways that are targeted by the drug-evoked structural plasticity.
Even within the frontal cortex, the excitatory pyramidal neurons are not a homogenous population, but instead consist of subtypes that differ by their projection targets and laminar position149,150. Most studies of drug-evoked turnover of dendritic spines rely on transgenic mice that preferentially express fluorescent proteins in the pyramidal tract subtype of pyramidal neurons in layer 5 of the neocortex150,151, but other neuronal subpopulations could also contribute to antidepressant drug action, such as layer 2/3 pyramidal neurons104, 28. This limitation could be rectified by using newer methods that enable genetic access to other excitatory cell types in mice, such as viruses with cloned-in cell-specific enhancers152. Moreover, pyramidal neurons are embedded within cortical microcircuits, with extensive connections to local GABAergic inhibitory interneurons. Although most synaptic inputs onto dendrites are excitatory, with an estimated excitatory-to-inhibitory input ratio of 20:1153, the few inhibitory connections can powerfully modulate dendritic excitability154,155. Therefore, inhibitory connections are postulated to have essential roles in regulating drug-evoked plasticity100. Inhibitory synapses are plastic like their excitatory counterparts156. The extent to which inhibitory plasticity might contribute to drug action is unknown.
Conclusions
Dendritic spines are the sites for excitatory synaptic connections in cortical pyramidal neurons. Evidence indicates that excitatory synaptic deficits occur in depression. Over the last decade, in vivo longitudinal imaging studies have begun to reveal how drugs with established or putative rapid-acting antidepressant effects in humans, including ketamine, psilocybin and other psychedelic analogues, alter the turnover dynamics and morphology of dendritic spines in the mouse frontal cortex. Different forms of structural remodelling can be measured, such as spine number density, spine size, turnover rates and persistence, with each providing different insights into the underlying biological changes. The future presents exciting opportunities as well as hurdles for using neuronal rewiring for drug development and reverse translation to understand other antidepressant treatment options with rapid therapeutic onset. For these reasons, in vivo structural plasticity could provide crucial information into the mechanism of action underlying the therapeutic effects of antidepressant interventions.
Supplementary Material
Acknowledgments
We thank Neil Savalia (Yale University) for feedback and Ling-Xiao Shao (Cornell University) for help with making the figures. The authors acknowledge the support of NIH/NIMH grants R01MH121848, R01MH128217, R01MH137047 (A.C.K.), One Mind–COMPASS Rising Star Award (A.C.K.), NIH/NINDS training grant T32NS041228 (C. Liao), NIH/NIGMS training grant T32GM152349 (A.D.), NIH/NIMH grants MH123154, MH118451, MH109685 (C. Liston), NIH/NIDA grant DA047851 (C. Liston), and grants from One Mind, Hartwell Foundation, Rita Allen Foundation, Klingenstein-Simons Foundation Fund, Brain and Behavior Research Foundation, Hope for Depression Research Foundation, and Pritzker Neuropsychiatric Disorders Research Consortium (C. Liston).
Competing interests
A.C.K. has been a scientific advisor or consultant for Boehringer Ingelheim, Empyrean Neuroscience, Freedom Biosciences, and Psylo. A.C.K. has received research support from Intra-Cellular Therapies. C. Liston has served as a scientific adviser or consultant for Brainify.AI, Compass Pathways, Delix Therapeutics, and Magnus Medical. The other authors report no competing interests.
Footnotes
Supplementary information
Supplementary information is available for this paper.
References
- 1.DeFelipe J & Farinas I The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs. Prog Neurobiol 39, 563–607 (1992). [DOI] [PubMed] [Google Scholar]
- 2.Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N & Nakahara H Structure-stability-function relationships of dendritic spines. Trends Neurosci 26, 360–368 (2003). [DOI] [PubMed] [Google Scholar]
- 3.Luscher C & Malenka RC Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69, 650–663 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Robinson TE & Kolb B Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47, 33–46 (2004). [DOI] [PubMed] [Google Scholar]
- 5.Phoumthipphavong V, Barthas F, Hassett S & Kwan AC Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex. eNeuro 3, ENEURO.0133-0115.2016 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pryazhnikov E et al. Longitudinal two-photon imaging in somatosensory cortex of behaving mice reveals dendritic spine formation enhancement by subchronic administration of low-dose ketamine. Sci Rep 8, 6464 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ng LHL et al. Ketamine and selective activation of parvalbumin interneurons inhibit stress-induced dendritic spine elimination. Transl Psychiatry 8, 272 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Moda-Sava RN et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364, eaat8078 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study demonstrates that ketamine restores dendritic spines eliminated due to chronic corticosterone treatment, and that disrupting ketamine-induced new spines blocks ketamine’s ability to alleviate motivated escape behavior in mice.
- 9.Shao LX et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544 e2534 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]; This work demonstrates in vivo that a single dose of the classic psychedelic psilocybin has rapid and long-lasting effects on structural neural plasticity in mouse medial frontal cortex.
- 10.Jefferson SJ et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology 48, 1257–1266 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cameron LP et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474–479 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lu J et al. An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Mol Psychiatry 26, 6237–6252 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Krystal JH, Abdallah CG, Sanacora G, Charney DS & Duman RS Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron 101, 774–778 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Vollenweider FX & Preller KH Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21, 611–624 (2020). [DOI] [PubMed] [Google Scholar]
- 15.McClure-Begley TD & Roth BL The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov 21, 463–473 (2022). [DOI] [PubMed] [Google Scholar]
- 16.Thompson SM et al. An excitatory synapse hypothesis of depression. Trends Neurosci 38, 279–294 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Duman RS & Aghajanian GK Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ousdal OT et al. The Neurobiological Effects of Electroconvulsive Therapy Studied Through Magnetic Resonance: What Have We Learned, and Where Do We Go? Biological Psychiatry 91, 540–549 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jannati A, Oberman LM, Rotenberg A & Pascual-Leone A Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. Neuropsychopharmacology 48, 191–208 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zarate CA Jr. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63, 856–864 (2006). [DOI] [PubMed] [Google Scholar]
- 21.Husain MM et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 65, 485–491 (2004). [DOI] [PubMed] [Google Scholar]
- 22.Cole EJ et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry 179, 132–141 (2022). [DOI] [PubMed] [Google Scholar]
- 23.Xu T et al. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature 462, 915–919 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Yang G, Pan F & Gan WB Stably maintained dendritic spines are associated with lifelong memories. Nature 462, 920–924 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Trachtenberg JT et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 420, 788–794 (2002). [DOI] [PubMed] [Google Scholar]
- 26.Robinson TE & Kolb B Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 11, 1598–1604 (1999). [DOI] [PubMed] [Google Scholar]
- 27.Oliva HNP et al. Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Molecular Psychiatry 29, 2873–2885 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kang HJ et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18, 1413–1417 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study reports synapse loss and lower expression of synapse-function-related genes in the dorsolateral prefrontal cortex of individuals with major depressive disorder.
- 29.Feyissa AM, Chandran A, Stockmeier CA & Karolewicz B Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33, 70–75 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Holmes SE et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun 10, 1529 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study provides the first in vivo evidence that lower synaptic density, measured via PET imaging with the SV2A radioligand, is linked to altered network function and depressive symptoms.
- 31.Hasler G et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64, 193–200 (2007). [DOI] [PubMed] [Google Scholar]
- 32.Auer DP et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47, 305–313 (2000). [DOI] [PubMed] [Google Scholar]
- 33.Yüksel C & Öngür D Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders. Biological Psychiatry 68, 785–794 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Howard DM et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience 22, 343–352 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Levey DF et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience 24, 954–963 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Howard DM et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun 9, 1470 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Wray NR et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50, 668–681 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Labonté B et al. Sex-specific transcriptional signatures in human depression. Nature Medicine 23, 1102–1111 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Nagy C et al. Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nature Neuroscience 23, 771–781 (2020). [DOI] [PubMed] [Google Scholar]
- 40.Sheline YI, Wang PW, Gado MH, Csernansky JG & Vannier MW Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 93, 3908–3913 (1996). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Drevets WC et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824–827 (1997). [DOI] [PubMed] [Google Scholar]
- 42.Goodkind M et al. Identification of a Common Neurobiological Substrate for Mental Illness. JAMA Psychiatry 72, 305–315 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Schmaal L et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Molecular Psychiatry 22, 900–909 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Fried EI & Kievit RA The volumes of subcortical regions in depressed and healthy individuals are strikingly similar: a reinterpretation of the results by Schmaal et al. Molecular Psychiatry 21, 724–725 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Rajkowska G et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45, 1085–1098 (1999). [DOI] [PubMed] [Google Scholar]
- 46.Stefan K, Kunesch E, Benecke R, Cohen LG & Classen J Mechanisms of enhancement of human motor cortex excitability induced by interventional paired associative stimulation. The Journal of Physiology 543, 699–708 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Player MJ et al. Neuroplasticity in Depressed Individuals Compared with Healthy Controls. Neuropsychopharmacology 38, 2101–2108 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Kuhn M et al. State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression. Neuropsychopharmacology 41, 1521–1529 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Noda Y et al. Impaired neuroplasticity in the prefrontal cortex in depression indexed through paired associative stimulation. Depression and Anxiety 35, 448–456 (2018). [DOI] [PubMed] [Google Scholar]
- 50.Huang Y-Z et al. Plasticity induced by non-invasive transcranial brain stimulation: A position paper. Clinical Neurophysiology 128, 2318–2329 (2017). [DOI] [PubMed] [Google Scholar]
- 51.Yan C-G et al. Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. Proceedings of the National Academy of Sciences 116, 9078–9083 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Javaheripour N et al. Altered resting-state functional connectome in major depressive disorder: a mega-analysis from the PsyMRI consortium. Translational Psychiatry 11, 511 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Kaiser RH, Andrews-Hanna JR, Wager TD & Pizzagalli DA Large-Scale Network Dysfunction in Major Depressive Disorder. JAMA Psychiatry 72, 603–611 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Brandl F et al. Common and specific large-scale brain changes in major depressive disorder, anxiety disorders, and chronic pain: a transdiagnostic multimodal meta-analysis of structural and functional MRI studies. Neuropsychopharmacology 47, 1071–1080 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Drysdale AT et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine 23, 28–38 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Dunlop K et al. Dimensional and Categorical Solutions to Parsing Depression Heterogeneity in a Large Single-Site Sample. Biological Psychiatry 96, 422–434 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Tozzi L et al. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine 30, 2076–2087 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Winter NR et al. Quantifying Deviations of Brain Structure and Function in Major Depressive Disorder Across Neuroimaging Modalities. JAMA Psychiatry 79, 879–888 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Siegel JS et al. Psilocybin desynchronizes the human brain. Nature 632, 131–138 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lynch CJ et al. Frontostriatal salience network expansion in individuals in depression. Nature 633, 624–633 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.O’Reardon JP et al. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry 62, 1208–1216 (2007). [DOI] [PubMed] [Google Scholar]
- 62.van Rooij SJH, Arulpragasam AR, McDonald WM & Philip NS Accelerated TMS - moving quickly into the future of depression treatment. Neuropsychopharmacology 49, 128–137 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Oliveira-Maia AJ, Press D & Pascual-Leone A Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation. Brain Stimulation 10, 787–794 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Cole J et al. Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder. JAMA Psychiatry 79, 1153–1161 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Abdallah CG et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43, 2154–2160 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Erchinger VJ, Ersland L, Aukland SM, Abbott CC & Oltedal L Magnetic Resonance Spectroscopy in Depressed Subjects Treated With Electroconvulsive Therapy—A Systematic Review of Literature. Frontiers in Psychiatry 12, 608857 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Njau S et al. Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. Journal of Psychiatry & Neuroscience 42, 6–16 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Li N et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study reveals that ketamine rapidly activates the mTOR pathway, enhancing synaptic signaling and promoting the formation and function of new spine synapses in the rat prefrontal cortex, and that blocking mTOR signaling negates ketamine’s effects.
- 69.Ly C et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep 23, 3170–3182 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study demonstrates that the application of a wide range of serotonergic psychedelics can cause neurite formation and spine growth in cultured cortical neurons.
- 70.de la Fuente Revenga M et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep 37, 109836 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Maynard KR, Hobbs JW, Rajpurohit SK & Martinowich K Electroconvulsive seizures influence dendritic spine morphology and BDNF expression in a neuroendocrine model of depression. Brain Stimulation 11, 856–859 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Cambiaghi M et al. High-frequency repetitive transcranial magnetic stimulation enhances layer II/III morphological dendritic plasticity in mouse primary motor cortex. Behavioural Brain Research 410, 113352 (2021). [DOI] [PubMed] [Google Scholar]
- 73.Vlachos A et al. Repetitive Magnetic Stimulation Induces Functional and Structural Plasticity of Excitatory Postsynapses in Mouse Organotypic Hippocampal Slice Cultures. The Journal of Neuroscience 32, 17514–17523 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Shi Y et al. Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO). Nat Neurosci 25, 317–329 (2022). [DOI] [PubMed] [Google Scholar]; This study reports the effects of diazepam treatments on structural plasticity of dendritic spines, which could explain why long-term use of the drug leads to cognitive decline.
- 75.Munoz-Cuevas FJ, Athilingam J, Piscopo D & Wilbrecht L Cocaine-induced structural plasticity in frontal cortex correlates with conditioned place preference. Nat Neurosci 16, 1367–1369 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]; This work demonstrates that cocaine administration leads to an increase in the formation of new dendritic spines in the frontal cortex, which correlates with cocaine-induced conditioned place preference, suggesting that these structural changes may play a role in stimulant-related learning and drug-seeking behavior.
- 76.Shapovalov Y et al. Fluoxetine modulates breast cancer metastasis to the brain in a murine model. BMC Cancer 14, 598 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Bowling H et al. Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity. Sci Signal 7, ra4 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Yang G, Chang PC, Bekker A, Blanck TJ & Gan WB Transient effects of anesthetics on dendritic spines and filopodia in the living mouse cortex. Anesthesiology 115, 718–726 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Lai B, Li M, Hu W, Li W & Gan WB The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning. Dev Neurobiol 78, 859–872 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Komorowska-Muller JA et al. Chronic low-dose Delta(9)-tetrahydrocannabinol (THC) treatment stabilizes dendritic spines in 18-month-old mice. Sci Rep 13, 1390 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Zanos P et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev 70, 621–660 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Popova V et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry 176, 428–438 (2019). [DOI] [PubMed] [Google Scholar]
- 83.Nichols DE Psychedelics. Pharmacol Rev 68, 264–355 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Kwan AC, Olson DE, Preller KH & Roth BL The neural basis of psychedelic action. Nat Neurosci 25, 1407–1419 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Grof S, Goodman LE, Richards WA & Kurland A LSD-assisted psychotherapy in patients with terminal cancer. International pharmacopsychiatry 8, 129–144 (1973). [DOI] [PubMed] [Google Scholar]
- 86.Goodwin GM et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 387, 1637–1648 (2022). [DOI] [PubMed] [Google Scholar]
- 87.Raison CL et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA 330, 843–853 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Reckweg J et al. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Front Pharmacol 12, 760671 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Reddy DS Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 186, 113–137 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Nestler EJ, Hyman SE & Malenka RC Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. Second Edition., (McGraw-Hill, 2009). [Google Scholar]
- 91.Wu M, Minkowicz S, Dumrongprechachan V, Hamilton P & Kozorovitskiy Y Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms. Biological Psychiatry 89, 1096–1105 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study shows, using two-photon uncaging in mouse brain slices, that ketamine increases the likelihood for glutamate-evoked spinogenesis, which precedes the changes in dendritic spine density.
- 92.Sequeira MK, Swanson AM, Kietzman HW & Gourley SL Cocaine and habit training cause dendritic spine rearrangement in the prelimbic cortex. iScience 26, 106240 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Maletic-Savatic M, Malinow R & Svoboda K Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283, 1923–1927 (1999). [DOI] [PubMed] [Google Scholar]
- 94.Knott GW, Holtmaat A, Wilbrecht L, Welker E & Svoboda K Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci 9, 1117–1124 (2006). [DOI] [PubMed] [Google Scholar]; This work shows that in the barrel cortex of adult mice, new dendritic spines initially form without synapses, but if the new spines would persist for more than four days then they are likely to develop synapses.
- 95.Holtmaat A, Wilbrecht L, Knott GW, Welker E & Svoboda K Experience-dependent and cell-type-specific spine growth in the neocortex. Nature 441, 979–983 (2006). [DOI] [PubMed] [Google Scholar]
- 96.Stepanyants A, Hof PR & Chklovskii DB Geometry and structural plasticity of synaptic connectivity. Neuron 34, 275–288 (2002). [DOI] [PubMed] [Google Scholar]
- 97.Isaac JT, Nicoll RA & Malenka RC Evidence for silent synapses: implications for the expression of LTP. Neuron 15, 427–434 (1995). [DOI] [PubMed] [Google Scholar]
- 98.Liao D, Scannevin RH & Huganir R Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors. J Neurosci 21, 6008–6017 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study demonstrates that spontaneous synaptic activity activates NMDA receptors in silent synapses, leading to the rapid (within minutes) recruitment of AMPA receptors and increased frequency of miniature EPSCs.
- 99.Vardalaki D, Chung K & Harnett MT Filopodia are a structural substrate for silent synapses in adult neocortex. Nature 612, 323–327 (2022). [DOI] [PubMed] [Google Scholar]
- 100.Savalia NK, Shao LX & Kwan AC A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. Trends Neurosci 44, 260–275 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Kavalali ET & Monteggia LM Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders. Neuron 106, 715–726 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Holtmaat AJ et al. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 45, 279–291 (2005). [DOI] [PubMed] [Google Scholar]
- 103.Hill TC & Zito K LTP-Induced Long-Term Stabilization of Individual Nascent Dendritic Spines. The Journal of Neuroscience 33, 678–686 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Lupien SJ, McEwen BS, Gunnar MR & Heim C Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 10, 434–445 (2009). [DOI] [PubMed] [Google Scholar]
- 105.Gyles TM, Nestler EJ & Parise EM Advancing preclinical chronic stress models to promote therapeutic discovery for human stress disorders. Neuropsychopharmacology 49, 215–226 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Tanaka M, Szabó Á & Vécsei l. Preclinical modeling in depression and anxiety: Current challenges and future research directions. Advances in Clinical and Experimental Medicine 32, 505–509 (2023). [DOI] [PubMed] [Google Scholar]
- 107.Cook SC & Wellman CL Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol 60, 236–248 (2004). [DOI] [PubMed] [Google Scholar]
- 108.Radley JJ et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 125, 1–6 (2004). [DOI] [PubMed] [Google Scholar]
- 109.Radley JJ et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 16, 313–320 (2006). [DOI] [PubMed] [Google Scholar]
- 110.Liu RJ & Aghajanian GK Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci U S A 105, 359–364 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Chen CC, Lu J, Yang R, Ding JB & Zuo Y Selective activation of parvalbumin interneurons prevents stress-induced synapse loss and perceptual defects. Mol Psychiatry 23, 1614–1625 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Dromard Y, Arango-Lievano M, Fontanaud P, Tricaud N & Jeanneteau F Dual imaging of dendritic spines and mitochondria in vivo reveals hotspots of plasticity and metabolic adaptation to stress. Neurobiol Stress 15, 100402 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Liston C & Gan WB Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo. Proc Natl Acad Sci U S A 108, 16074–16079 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Ali F et al. Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat Commun 11, 72 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Nestler EJ & Hyman SE Animal models of neuropsychiatric disorders. Nat Neurosci 13, 1161–1169 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Holtmaat A et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc 4, 1128–1144 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]; This protocol details the method for creating a chronic cranial window in mice that enables long-term, high-resolution two-photon imaging of dendritic spines in the cerebral cortex.
- 117.Hennig MH, Fernholz MHP, Guggiana Nilo DA, Bonhoeffer T & Kist AM DeepD3, an open framework for automated quantification of dendritic spines. PLOS Computational Biology 20, e1011774 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Vidaurre-Gallart I et al. A Deep Learning-Based Workflow for Dendritic Spine Segmentation. Front Neuroanat 16, 817903 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Verstraelen P et al. Image-Based Profiling of Synaptic Connectivity in Primary Neuronal Cell Culture. Frontiers in Neuroscience 12, 389 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Savage JT et al. SynBot is an open-source image analysis software for automated quantification of synapses. Cell Reports Methods 4, 100861 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Avior Y et al. Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response. Translational Psychiatry 11, 201 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Sadakane O et al. In VivoTwo-Photon Imaging of Dendritic Spines in Marmoset Neocortex. eneuro 2, e0019–15.2015 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Chen M, Qi J, Poo M & Yang Y Stability and dynamics of dendritic spines in macaque prefrontal cortex. National Science Review 9, nwac125 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Holmes SE et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry 27, 2273–2281 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Vande Casteele T et al. Preliminary evidence for preserved synaptic density in late-life depression. Translational Psychiatry 14, 145 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Asch RH, Abdallah CG, Carson RE & Esterlis I Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression. Neuropsychopharmacology, Online ahead of print 10.1038/s41386-024-01913-3 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Johansen A et al. Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. Molecular Psychiatry 28, 4272–4279 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Angarita GA et al. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans. Addiction Biology 27, e13123 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Liston C et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci 26, 7870–7874 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Hayashi-Takagi A et al. Labelling and optical erasure of synaptic memory traces in the motor cortex. Nature 525, 333–338 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Kozyrev V, Eysel UT & Jancke D Voltage-sensitive dye imaging of transcranial magnetic stimulation-induced intracortical dynamics. Proceedings of the National Academy of Sciences 111, 13553–13558 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Romero MC, Davare M, Armendariz M & Janssen P Neural effects of transcranial magnetic stimulation at the single-cell level. Nature Communications 10, 2642 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Murphy SC, Palmer LM, Nyffeler T, Müri RM & Larkum ME Transcranial magnetic stimulation (TMS) inhibits cortical dendrites. eLife 5, e13598 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Tang AD et al. Subthreshold repetitive transcranial magnetic stimulation drives structural synaptic plasticity in the young and aged motor cortex. Brain Stimulation 14, 1498–1507 (2021). [DOI] [PubMed] [Google Scholar]
- 135.Williams LM Precision psychiatry: a neural circuit taxonomy for depression and anxiety. The Lancet Psychiatry 3, 472–480 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Menon V Large-scale brain networks and psychopathology: a unifying triple network model. Trends in Cognitive Sciences 15, 483–506 (2011). [DOI] [PubMed] [Google Scholar]
- 137.Nestler EJ et al. Neurobiology of depression. Neuron 34, 13–25 (2002). [DOI] [PubMed] [Google Scholar]
- 138.Yuen EY et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73, 962–977 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Vyas A, Mitra R, Shankaranarayana Rao BS & Chattarji S Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 22, 6810–6818 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Patel D, Anilkumar S, Chattarji S & Buwalda B Repeated social stress leads to contrasting patterns of structural plasticity in the amygdala and hippocampus. Behavioural Brain Research 347, 314–324 (2018). [DOI] [PubMed] [Google Scholar]
- 141.Cerniauskas I et al. Chronic Stress Induces Activity, Synaptic, and Transcriptional Remodeling of the Lateral Habenula Associated with Deficits in Motivated Behaviors. Neuron 104, 899–915 e898 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Li B et al. Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature 470, 535–539 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Shansky RM, Hamo C, Hof PR, McEwen BS & Morrison JH Stress-induced dendritic remodeling in the prefrontal cortex is circuit specific. Cereb Cortex 19, 2479–2484 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Barrientos C et al. Cocaine-Induced Structural Plasticity in Input Regions to Distinct Cell Types in Nucleus Accumbens. Biol Psychiatry 84, 893–904 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.McAvoy K, Russo C, Kim S, Rankin G & Sahay A Fluoxetine induces input-specific hippocampal dendritic spine remodeling along the septotemporal axis in adulthood and middle age. Hippocampus 25, 1429–1446 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146.Ali F et al. Inhibitory regulation of calcium transients in prefrontal dendritic spines is compromised by a nonsense Shank3 mutation. Mol Psychiatry 26, 1945–1966 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.Beier KT et al. Rabies screen reveals GPe control of cocaine-triggered plasticity. Nature 549, 345–350 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Zingg B, Peng B, Huang J, Tao HW & Zhang LI Synaptic Specificity and Application of Anterograde Transsynaptic AAV for Probing Neural Circuitry. The Journal of Neuroscience 40, 3250–3267 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Anastasiades PG & Carter AG Circuit organization of the rodent medial prefrontal cortex. Trends Neurosci 44, 550–563 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150.Baker A et al. Specialized Subpopulations of Deep-Layer Pyramidal Neurons in the Neocortex: Bridging Cellular Properties to Functional Consequences. J Neurosci 38, 5441–5455 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Guo C et al. Single-axon level morphological analysis of corticofugal projection neurons in mouse barrel field. Scientific Reports 7, 2846 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Graybuck LT et al. Enhancer viruses for combinatorial cell-subclass-specific labeling. Neuron 109, 1449–1464.e1413 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Kasthuri N et al. Saturated Reconstruction of a Volume of Neocortex. Cell 162, 648–661 (2015). [DOI] [PubMed] [Google Scholar]
- 154.Chiu CQ et al. Compartmentalization of GABAergic inhibition by dendritic spines. Science 340, 759–762 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Larkum ME, Zhu JJ & Sakmann B A new cellular mechanism for coupling inputs arriving at different cortical layers. Nature 398, 338–341 (1999). [DOI] [PubMed] [Google Scholar]
- 156.Chen JL et al. Clustered dynamics of inhibitory synapses and dendritic spines in the adult neocortex. Neuron 74, 361–373 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Denk W, Strickler JH & Webb WW Two-photon laser scanning fluorescence microscopy. Science 248, 73–76 (1990). [DOI] [PubMed] [Google Scholar]
- 158.Yang G, Pan F, Parkhurst CN, Grutzendler J & Gan WB Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat Protoc 5, 201–208 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Gray EG Electron microscopy of synaptic contacts on dendrite spines of the cerebral cortex. Nature 183, 1592–1593 (1959). [DOI] [PubMed] [Google Scholar]
- 160.Larkman AU Dendritic morphology of pyramidal neurones of the visual cortex of the rat: III. Spine distributions. J Comp Neurol 306, 332–343 (1991). [DOI] [PubMed] [Google Scholar]
- 161.Turner NL et al. Reconstruction of neocortex: Organelles, compartments, cells, circuits, and activity. Cell 185, 1082–1100 e1024 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 162.Nishiyama J & Yasuda R Biochemical Computation for Spine Structural Plasticity. Neuron 87, 63–75 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 163.Koch C & Zador A The Function of Dendritic Spines - Devices Subserving Biochemical Rather Than Electrical Compartmentalization. Journal of Neuroscience 13, 413–422 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 164.Huttenlocher PR Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res 163, 195–205 (1979). [DOI] [PubMed] [Google Scholar]
- 165.Penzes P, Cahill ME, Jones KA, VanLeeuwen JE & Woolfrey KM Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 14, 285–293 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166.Engert F & Bonhoeffer T Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399, 66–70 (1999). [DOI] [PubMed] [Google Scholar]
- 167.Arellano JI, Espinosa A, Fairen A, Yuste R & DeFelipe J Non-synaptic dendritic spines in neocortex. Neuroscience 145, 464–469 (2007). [DOI] [PubMed] [Google Scholar]
- 168.Matsuzaki M, Honkura N, Ellis-Davies GC & Kasai H Structural basis of long-term potentiation in single dendritic spines. Nature 429, 761–766 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 169.Holler S, Kostinger G, Martin KAC, Schuhknecht GFP & Stratford KJ Structure and function of a neocortical synapse. Nature 591, 111–116 (2021). [DOI] [PubMed] [Google Scholar]
- 170.Feng G et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41–51 (2000). [DOI] [PubMed] [Google Scholar]
- 171.Zipfel WR, Williams RM & Webb WW Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol 21, 1369–1377 (2003). [DOI] [PubMed] [Google Scholar]
- 172.Ofer N, Berger DR, Kasthuri N, Lichtman JW & Yuste R Ultrastructural analysis of dendritic spine necks reveals a continuum of spine morphologies. Dev Neurobiol 81, 746–757 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 173.Grutzendler J, Kasthuri N & Gan WB Long-term dendritic spine stability in the adult cortex. Nature 420, 810–812 (2002). [DOI] [PubMed] [Google Scholar]
- 174.Holtmaat A, De Paola V, Wilbrecht L & Knott GW Imaging of experience-dependent structural plasticity in the mouse neocortex in vivo. Behav Brain Res 192, 20–25 (2008). [DOI] [PubMed] [Google Scholar]
- 175.Attardo A, Fitzgerald JE & Schnitzer MJ Impermanence of dendritic spines in live adult CA1 hippocampus. Nature 523, 592–596 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 176.Davoudian PA, Shao LX & Kwan AC Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chem Neurosci 14, 468–480 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]; This study uses whole-brain imaging to map the effects of ketamine and psilocybin administration on c-Fos expression in mice, highlighting numerous cortical and subcortical brain regions with similar or distinct changes.
- 177.Rijsketic DR et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacology 48, 1798–1807 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 178.Chenani A et al. Repeated stress exposure leads to structural synaptic instability prior to disorganization of hippocampal coding and impairments in learning. Transl Psychiatry 12, 381 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 179.Bosch M et al. Structural and molecular remodeling of dendritic spine substructures during long-term potentiation. Neuron 82, 444–459 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 180.Harward SC et al. Autocrine BDNF-TrkB signalling within a single dendritic spine. Nature 538, 99–103 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 181.Sun C et al. The prevalence and specificity of local protein synthesis during neuronal synaptic plasticity. Sci Adv 7, eabj0790 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 182.Butko MT et al. Fluorescent and photo-oxidizing TimeSTAMP tags track protein fates in light and electron microscopy. Nat Neurosci 15, 1742–1751 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 183.Shepherd JD & Huganir RL The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 23, 613–643 (2007). [DOI] [PubMed] [Google Scholar]
- 184.Stein IS & Zito K Dendritic Spine Elimination: Molecular Mechanisms and Implications. Neuroscientist 25, 27–47 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 185.Eroglu C & Barres BA Regulation of synaptic connectivity by glia. Nature 468, 223–231 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 186.Tremblay ME, Lowery RL & Majewska AK Microglial interactions with synapses are modulated by visual experience. PLoS Biol 8, e1000527 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 187.Duman R, Aghajanian G, Sanacora G et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22, 238–249 (2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
